The Prognostic Value of C‐Reactive Protein‐Albumin‐Lymphocyte (CALLY) Index in Predicting In‐Hospital Mortality After Primary Percutaneous Coronary Intervention in Patients With ST‐Elevation Myocardial Infarction (STEMI)

BACKGROUND: The C-reactive protein-albumin-lymphocyte (CALLY) index is a clinically feasible biomarker for cancer prognosis. CALLY index and post-primary percutaneous coronary intervention (pPCI) in-hospital mortality in patients with ST-elevation myocardial infarction (STEMI) remains unclear, despite evidence showing the predictive value of the CALLY index in various cancers. AIMS: This study aims to examine the relationship between the CALLY index assessed at hospital admission and in-hospital mortality in STEMI patients. METHODS: The population for this retrospective study comprised 1423 consecutive patients diagnosed with STEMI who underwent pPCI. Out of these, 1133 patients were selected for the study sample and were divided into two groups based on the median CALLY index value of 3.03. In-hospital mortality rates during the follow-up period were obtained from the registry. RESULTS: The study's primary outcome, that is, in-hospital mortality, was significantly higher in patients with a CALLY index ≤ 6.15 than in those with a CALLY index > 6.15 (38 [6.7%] vs. 7 [1.2%], p < 0.001). Univariate and multivariate Cox proportional hazard analyses revealed that the CALLY index is independently associated with in-hospital mortality. CALLY index optimal cut-off value of ≤ 3.03 predicted in-hospital mortality with 75.5% sensitivity and 78.2% specificity. CONCLUSION: This study's findings indicate that the CALLY index may be a significant independent predictor of in-hospital mortality in patients with STEMI treated with pPCI. Those with a lower CALLY index are at a higher risk of experiencing in-hospital mortality.